Adeza’s Gestiva Review To Consider The Validity Of Pivotal Trial’s Primary Endpoint
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Reproductive Health Drugs Advisory Committee will discuss the preterm birth agent during an Aug. 29 meeting.